A recent study of approximately 3,000 patients by the Mayo Clinic in JAMA Oncology (Samadder et al) has identified that up to a third of patients on standard cancer treatment protocols required changes in their treatment once genomic testing had identified more suitable treatments for their cancer.
Furthermore, inherited mutations were missed in half of the patients using standard testing, but were subsequently picked up using NGS genomic testing.
The risk of developing several cancers is closely linked to hereditary factors. Identifying a germline predisposition among patients and their families may have beneficial implications for required screening, choice of treatment and other supportive interventions.
Studies such as this confirm the beneficial impact of wide-spread genomic testing for patient outcomes.
Through ConnectGene Care, we can assess your current treatment suitability and hereditary risk factors utilising genomic testing to ensure your treatment is personalised to your needs.
While genomic testing remains relatively expensive compared to standard screening protocols, working with ConnectGene Care, we can help you identify the most appropriate tests at a price point suitable for your financial situation.
- Samadder NJ, Riegert-Johnson D, Boardman L, et al. “Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome”. JAMA Oncol. Published online October 30, 2020. doi:10.1001/jamaoncol.2020.6252.
STAY IN THE KNOW
Keep me updated on new cancer treatment and genomic
testing developments from ConnectGene Care